Kyoung Kim, MD
Internal Medicine · Anaheim, CANPI 1477882215
Payments from drug & device makers
Across 298 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Regeneron Healthcare Solutions, Inc.$912
- AstraZeneca$818
- AbbVie$573
- Lilly USA, LLC$551
- Boehringer Ingelheim$458
- plus $3K from 28 others
What the payments were for
- Travel & lodging$1632%
- Food & beverage$7,60998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 51 | $1,409 |
| Regeneron Healthcare Solutions, Inc. | 32 | $912 |
| AstraZeneca | 34 | $818 |
| AbbVie | 20 | $573 |
| Lilly USA, LLC | 18 | $551 |
| Boehringer Ingelheim | 20 | $458 |
| Merck | 17 | $422 |
| Bayer | 11 | $340 |
| Ironwood Pharmaceuticals, Inc | 12 | $266 |
| Nestle Healthcare Nutrition Inc. | 13 | $236 |
| Amarin Pharma, Inc. | 10 | $233 |
| GSK | 12 | $197 |
| Seaspine Orthopedics Corporation | 1 | $157 |
| Exact Sciences | 6 | $151 |
| Pfizer | 6 | $151 |
| Johnson & Johnson | 1 | $122 |
| Eisai Inc. | 6 | $119 |
| Sanofi | 1 | $108 |
| Novartis | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $64 |
| Astellas Pharma US Inc | 3 | $62 |
| Almatica Pharma LLC | 3 | $60 |
| Scilex Pharmaceuticals Inc. | 3 | $60 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Dova Pharmaceuticals | 1 | $23 |
| IBSA Pharma Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Novo Nordisk | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,772 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 402 | $325,135 |
| MounjaroTirzepatide | 201 | $208,173 |
| CreonLipase/Protease/Amylase | 113 | $126,012 |
| JardianceEmpagliflozin | 139 | $125,459 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 52 | $125,168 |
| Dupixent PenDupilumab | 24 | $88,995 |
| VascepaIcosapent Ethyl | 210 | $88,727 |
| LinzessLinaclotide | 133 | $86,883 |
| KerendiaFinerenone | 89 | $70,901 |
| ProliaDenosumab | 40 | $68,174 |
| TrulicityDulaglutide | 60 | $65,213 |
| RybelsusSemaglutide | 45 | $53,547 |
| OtezlaApremilast | 11 | $52,932 |
| TezspireTezepelumab-Ekko | 11 | $47,505 |
| NucalaMepolizumab | 11 | $40,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Tezspire | $818 | $372,640413 claims |
| Lilly USA, LLCMounjaro, Trulicity | $551 | $273,386261 claims |
| AmgenEvenity (2 Syringes), Prolia, Otezla | $1,409 | $246,274103 claims |
| AbbVieCreon, Linzess, Restasis | $573 | $233,233277 claims |
| Boehringer IngelheimJardiance | $458 | $125,459139 claims |
| Novo NordiskRybelsus, Ozempic | $20 | $89,08381 claims |
| GSKNucala, Trelegy Ellipta, Shingrix | $197 | $81,29880 claims |
| BayerKerendia | $340 | $70,90189 claims |
| MerckJanuvia, Janumet | $422 | $38,79564 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $40 | $37,23650 claims |
| PfizerEliquis, Prempro | $151 | $31,87065 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $24,79247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Anaheim
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.